TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2224167
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line chemotherapy (monthly FEC)
Study: 487347
Drug: Disulfiram implant
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram implant
Study: 487347
Drug: No-implant control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-implant control
Study: 26448264
Drug: Perampanel 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 2, 4, 8, or 12 mg
Study: 27869305
Drug: Perampanel 8
Normalized name: perampanel 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 8 mg (PGTCS group)
Study: 17945070
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae vaccination as an adjunct to anti-tuberculosis treatment
Study: 17945070
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-tuberculosis treatment without Mycobacterium vaccae vaccination)
Study: 16297299
Drug: Polyelectrolyte solution
Normalized name: SUPER-VIAL HYPERLYTE MULTIELECTROLYTE CONC INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyelectrolyte solution (group PS), 21 infants
Study: 17698196
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22)
Study: 17698196
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24)
Study: 17698196
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22)
Study: 17698196
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks (n = 22)
Study: 12421428
Drug: 50% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% insulin lispro and 50% neutral protamine lispro (Mix50)
Study: 10523401
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 1 (on awakening)
Study: 10523401
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 2 (8 hours after awakening)
Study: 10523401
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 3 (before bedtime)
Study: 10523401
Drug: Aspirin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (any time) for women with a positive tolerance-hyperbaric test
Study: 10523401
Drug: Aspirin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (any time)
Study: 388762
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) - 14 daily doses in addition to standard immunosuppressive therapy (azathioprine and prednisone)
Study: 388762
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) - 14 daily doses
Study: 31172407
Drug: GC+w‐iniparib (iniparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC+w‐iniparib (iniparib 11.2 mg/kg on days 1 and 8 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Study: 31172407
Drug: GC+tw‐iniparib (iniparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC+tw‐iniparib (iniparib 5.6 mg/kg on days 1, 4, 8, and 11 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Study: 23938061
Drug: Ropinirole (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.25 to 4 mg)
Study: 21761740
Drug: Maixuekang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maixuekang capsule
Study: 21761740
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular heparin calcium (Subilin)
Study: 21761740
Drug: Maixuekang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maixuekang capsule and low molecular heparin calcium (Subilin)
Study: 16413249
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omeprazole
Study: 21565525
Drug: Maternal age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal age, intimate partner violence, illicit drug and alcohol use during pregnancy, reproductive history
Study: 19092462
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 2% jelly
Study: 16284061
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg given twice on day 1 followed by 4 days of ethinyl estradiol (EE) 20 microg in the morning and placebo at night
Study: 16284061
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg given twice on day 1 followed by 4 days of twice daily placebo
Study: 11771434
Drug: Glyco A
Normalized name: glycolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyco A cream (12% glycolic acid)
Study: 11771434
Drug: Kefrane cream
Normalized name: Efrane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kefrane cream (0.05% retinoic acid)
Study: 3797105
Drug: Increased plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased plasma L-phenylalanine
Study: 3797105
Drug: Decreased plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased plasma L-phenylalanine
Study: 26903605
Drug: Intralesional pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional pentamidine (120 μg/mm² lesion area, 3 injections over 5 days)
Study: 26903605
Drug: Intralesional pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional pentamidine (240 μg/mm², 3 injections)
Study: 26903605
Drug: Intralesional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional therapy with antimony (3 injections over 5 days)
Study: 26903605
Drug: Intralesional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional therapy with antimony (5 injections over 11 days)
Study: 26903605
Drug: Intralesional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional therapy with antimony (5 injections)
Study: 18287130
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 mcg once daily
Study: 15200038
Drug: Transdermal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal treatment (n = 52)
Study: 15200038
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate ointment (n = 37)
Study: 9209220
Drug: Hydrocortisone hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone hemisuccinate 50 mg/kg
Study: 27430394
Drug: Anma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma therapy (Japanese massage, AMT), 40-min session per week for 8 weeks
Study: 27430394
Drug: Anma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma therapy (Japanese massage, AMT), single session
Study: 24633595
Drug: Supervised aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised aerobic exercise during chemotherapy (n = 78)
Study: 24633595
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise during chemotherapy (n = 82)
Study: 24633595
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis for estrogen receptor-positive tumors
Study: 24633595
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis for patients receiving ≥85% of planned chemotherapy
Study: 22533660
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with SBP target <130 mm Hg
Study: 22533660
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with SBP target <140 mm Hg
Study: 21109302
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (mainly atorvastatin 24 mg per day)
Study: 21109302
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no statin treatment)
Study: 21109302
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (mainly atorvastatin)
Study: 16463007
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg daily (men and premenopausal women) / 10 mg daily (postmenopausal women)
Study: 16463007
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg daily / 10 mg daily
Study: 12651757
Drug: Turbuhaler with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Study: 12651757
Drug: pMDI connected
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pMDI connected to Nebuhaler spacer with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Study: 8866702
Drug: GHB, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB, 15 mg/kg
Study: 8866702
Drug: GHB, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB, 30 mg/kg
Study: 1502480
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg or 800 mg)
Study: 20234783
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus amlodipine 5 mg
Study: 20234783
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg plus amlodipine 5 mg
Study: 25769960
Drug: Tai-chi group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai-chi group-based exercise program (60 minutes, twice weekly for 48 weeks)
Study: 19620850
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once daily at night for 12 weeks
Study: 16399263
Drug: Related prime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Related prime (e.g. 'piano')
Study: 10907154
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - dermatological standard treatment
Study: 9310109
Drug: Eltenac gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltenac gel
Study: 8376682
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone with converting enzyme inhibitors
Study: 27473306
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) influenza vaccine
Study: 27473306
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) influenza vaccine
Study: 25636721
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement intake
Study: 23972968
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg QD
Study: 21910510
Drug: Fimasartan 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 240 mg (fed state)
Study: 21910510
Drug: Fimasartan 20-480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 20-480 mg (fasted single doses)
Study: 21910510
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg (fasted repeated doses)
Study: 21910510
Drug: Fimasartan 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 360 mg (fasted repeated doses)
Study: 21910510
Drug: Fimasartan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (various doses)
Study: 21910510
Drug: Fimasartan (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (240 mg in fed state)
Study: 16923246
Drug: Low-dose antioxidant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antioxidant supplementation (nutritional doses)
Study: 12654439
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose Pd-103
Study: 12654439
Drug: No instances
Approvals — FDA: no, EMA: no, PMDA: no
Description: No instances of rectal ulceration or fistula reported
Study: 10600654
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg body weight)
Study: 3942496
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours of antibiotics
Study: 3942496
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of antibiotics
Study: 30177406
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy with 50Hz frequency, low intensity of 20Gauss, combined with Conventional physical therapy Protocol
Study: 30177406
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy Protocol
Study: 25534298
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi Chuan exercise sessions (Yang style) twice a week for 12 weeks
Study: 22893563
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg daily
Study: 20974993
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (orange juice and grapefruit juice)
Study: 14613569
Drug: Efalizumab (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (weekly subcutaneous administration)
Study: 9792934
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose IL-2 infusion combined with CTX-based chemotherapy
Study: 9792934
Drug: Triple chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple chemotherapy (CTX, etoposide and Ara-C)
Study: 7924128
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg daily for 12 weeks
Study: 7924128
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg daily for 12 weeks
Study: 4885025
Drug: sulphamethoxazole-trimethoprim combination
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphamethoxazole-trimethoprim combination (2:1 and 10:1)
Study: 4885025
Drug: sulphamethoxazole-trimethoprim combination
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphamethoxazole-trimethoprim combination (5:1)
Study: 31930678
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration (24 international units)
Study: 25848890
Drug: Sitting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting with Vitamin C (VIT) - 2 vitamin C tablets (1 g and 500 mg) ingested at 30 min and 1 h 30 min, respectively
Study: 16697850
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (outpatient behavioral therapy)
Study: 16697850
Drug: Added video
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added video instructions with standard therapy
Study: 16697850
Drug: Home uroflowmetry
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home uroflowmetry biofeedback with standard therapy
Study: 16697850
Drug: Home uroflowmetry
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home uroflowmetry biofeedback with standard therapy (per protocol analysis)
Study: 14990012
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin use for 30-60 months
Study: 11376916
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/kg ethanol)
Study: 11376916
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg caffeine, 0.0 g/kg ethanol)
Study: 11376916
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (0 mg caffeine)
Study: 9400342
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (up to 60 mg/d)
Study: 8480929
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses)
Study: 8480929
Drug: Ceftizoxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (2 doses)
Study: 3079009
Drug: Iron succinylprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron succinylprotein complex (80 mg of elemental iron daily)
Study: 3079009
Drug: Iron gluconate
Normalized name: Iron Gluconate 27mg Tablet
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron gluconate complex (125 mg of elemental iron daily)
Study: 29272211
Drug: omega‐3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega‐3 (1 g/twice daily)
Study: 29272211
Drug: cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: cranberry juice (200 ml, twice daily)
Study: 29272211
Drug: cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: cranberry juice enriched with omega‐3 (200 ml, containing 1 g omega‐3, twice daily)
Study: 26182775
Drug: Sub-fascial local
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-fascial local anaesthetic (LA) inguinal field block with 20 ml 0.5% bupivacaine, 20 ml 2% lignocaine with adrenaline, 20 ml normal saline, 3 ml NaHCO3
Study: 19160857
Drug: Intratympanic prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic prednisolone injection
Study: 19160857
Drug: Carbamazepine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (oral administration)
Study: 11372003
Drug: 1 mg/mL
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL aspartame
Study: 11372003
Drug: 2 mg/mL
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/mL aspartame
Study: 11372003
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg aspartame (in vivo)
Study: 9181653
Drug: Albendazole continuous
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole continuous therapy for 6 months
Study: 9181653
Drug: Albendazole discontinuous
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole discontinuous therapy for 6 courses of 4 weeks with a 2 week drug-free interval
Study: 3327669
Drug: Pirprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (400 mg, b.i.d.)
Study: 3327669
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg, b.i.d.)
Study: 31622777
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion at 1.5pmol/kg/min
Study: 31622777
Drug: GIP +
Normalized name: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP + GIP(3‐30)NH2 infusion
Study: 31622777
Drug: GIP(3‐30)NH2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP(3‐30)NH2 infusion
Study: 20957469
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (group 2)
Study: 15498060
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Study: 15498060
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Study: 8200219
Drug: 250 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 micrograms levonorgestrel in combination with 50 micrograms ethinylestradiol
Study: 8200219
Drug: 250 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 micrograms norgestimate in combination with 35 micrograms ethinylestradiol
Study: 3300988
Drug: Cefatrizine once
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine once daily (75 mg/kg/day)
Study: 3300988
Drug: Cefatrizine twice
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine twice daily (75 mg/kg/day)
Study: 3300988
Drug: Erythromycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (50 mg/kg/day in three divided doses)
Study: 30203327
Drug: Antidepressant monotherapies
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant monotherapies and combinations
Study: 30203327
Drug: Psychotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy alone or in combination with an antidepressant
Study: 17100723
Drug: Fluvastatin 40-80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40-80 mg daily
Study: 12795643
Drug: Insulin‐intensive conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐intensive conventional treatment (ICT)